Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,714,000 | 1,151,000 | 418,000 | 477,000 | 1,305,000 |
| Depreciation Amortization | 2,547,000 | 1,734,000 | 884,000 | 3,933,000 | 3,018,000 |
| Accounts receivable | -280,000 | -137,000 | -53,000 | -207,000 | -169,000 |
| Other Working Capital | -730,000 | -473,000 | -224,000 | 1,915,000 | -130,000 |
| Other Operating Activity | 1,284,000 | 77,000 | 83,000 | -548,000 | -94,000 |
| Operating Cash Flow | $4,535,000 | $2,352,000 | $1,108,000 | $5,570,000 | $3,930,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -23,000 | -42,000 | -5,000 | N/A | -98,000 |
| PPE Investments | -927,000 | -573,000 | -275,000 | -1,135,000 | -790,000 |
| Net Acquisitions | 5,000 | 5,000 | -25,000 | -11,141,000 | -7,585,000 |
| Purchase Of Investment | N/A | N/A | N/A | -210,000 | N/A |
| Sale Of Investment | N/A | N/A | N/A | 129,000 | N/A |
| Other Investing Activity | 85,000 | 73,000 | 67,000 | 2,739,000 | 2,007,000 |
| Investing Cash Flow | $-860,000 | $-537,000 | $-238,000 | $-9,618,000 | $-6,466,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 22,000 | 140,000 | 6,000 | -1,034,000 | -1,424,000 |
| Debt Issued | 4,011,000 | N/A | N/A | 6,742,000 | 0 |
| Debt Repayment | -8,279,000 | -7,280,000 | -5,979,000 | -8,650,000 | -2,508,000 |
| Common Stock Issued | 244,000 | 170,000 | 137,000 | 350,000 | 275,000 |
| Common Stock Repurchased | -134,000 | -131,000 | -128,000 | -117,000 | -106,000 |
| Dividend Paid | -1,479,000 | -985,000 | -491,000 | -1,849,000 | -1,385,000 |
| Other Financing Activity | 0 | 0 | 0 | -723,000 | -21,000 |
| Financing Cash Flow | $-5,615,000 | $-8,086,000 | $-6,455,000 | $-5,281,000 | $-5,169,000 |
| Exchange Rate Effect | -98,000 | -71,000 | 35,000 | 116,000 | 97,000 |
| Beginning Cash Position | 9,407,000 | 9,407,000 | 9,407,000 | 18,620,000 | 18,620,000 |
| End Cash Position | 7,369,000 | 3,065,000 | 3,857,000 | 9,407,000 | 11,012,000 |
| Net Cash Flow | $-2,038,000 | $-6,342,000 | $-5,550,000 | $-9,213,000 | $-7,608,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,535,000 | 2,352,000 | 1,108,000 | 5,570,000 | 3,930,000 |
| Capital Expenditure | -927,000 | -573,000 | -275,000 | -1,135,000 | -790,000 |
| Free Cash Flow | 3,608,000 | 1,779,000 | 833,000 | 4,435,000 | 3,140,000 |